Table 2.
Univariate analysis of the association between the clinical- and medication-related characteristics of respondents and their adherence to oral adjuvant endocrine therapy (n=157)
| Clinical- and medication-related characteristics | n (%) | Prevalence of high adherence (%)* | P† |
|---|---|---|---|
| Type of OAET taken for the past 1 month | |||
| Tamoxifen | 76 (48.4) | 31.6 | 0.023 |
| Aromatase inhibitors | 81 (51.6) | 49.4 | |
| Side effects | |||
| No side effects reported | 75 (47.8) | 45.3 | 0.265 |
| One or more side effects | 82 (52.2) | 36.6 | |
| Cancer stage at diagnosis | |||
| Stage 0 | 10 (6.4) | 50.0 | 0.293 |
| Stage 1 | 46 (29.3) | 32.6 | |
| Stage 2 | 69 (43.9) | 39.1 | |
| Stage 3 | 32 (20.4) | 53.1 | |
| Prior chemotherapy | |||
| No | 53 (33.8) | 34.0 | 0.216 |
| Yes | 104 (66.2) | 44.2 | |
| Years since first OAET | |||
| ≤2 | 73 (46.5) | 47.9 | 0.088 |
| >2 | 84 (53.5) | 34.5 | |
| Number of comorbidities | |||
| None | 78 (49.7) | 25.6 | <0.001 |
| ≥1 | 79 (50.3) | 55.7 | |
| Total number of chronic medications | |||
| ≤2 | 80 (51.0) | 27.5 | 0.001 |
| ≥3 | 77 (49.0) | 54.5 |
Patients who scored 4 on MMAS-4 were considered to have high adherence, †P value based on Chi-square test. OAET: Oral adjuvant endocrine therapy; MMAS-4: Morisky Medication Adherence Scale-4 items